Stocks of Acumen Pharmaceuticals Inc (NASDAQ:ABOS) traded higher last session on Wall Street, down -6.80% to $2.33.
ABOS stock price is now -28.53% away from the 50-day moving average and -34.15% away from the 200-day moving average. The market capitalization of the company currently stands at $139.99M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Deutsche Bank recently initiated with Buy rating for Acumen Pharmaceuticals Inc (NASDAQ: ABOS)., while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, OConnell Daniel Joseph, President and CEO sold 15,200 shares of the company’s stock on Jan 19 ’24. The stock was sold for $52,753 at an average price of $3.47. Upon completion of the transaction, the President and CEO now directly owns 502,485 shares in the company, valued at $1.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 19 ’24, Chief Legal Officer & Corp Sec Meisner Derek M sold 8,933 shares of the business’s stock. A total of $31,048 was realized by selling the stock at an average price of $3.48. This leaves the insider owning 108,867 shares of the company worth $0.25 million. A total of 26.14% of the company’s stock is owned by insiders.
During the past 12 months, Acumen Pharmaceuticals Inc has had a low of $1.81 and a high of $11.31. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 30.20, and a quick ratio of 30.20. The fifty day moving average price for ABOS is $3.2288 and a two-hundred day moving average price translates $3.519975 for the stock.
The latest earnings results from Acumen Pharmaceuticals Inc (NASDAQ: ABOS) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.28, beating analysts’ expectations of -0.35 by 0.07. This compares to -$0.28 EPS in the same period last year. The company reported revenue of $17.77 million for the quarter, compared to $13.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.32 percent.
